Analyst Price Targets — ASND
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 7, 2026 11:28 am | — | RBC Capital | $280.00 | $267.92 | TheFly | Ascendis Pharma price target raised to $280 from $275 at RBC Capital |
| May 15, 2026 12:22 pm | — | Evercore ISI | $329.00 | $241.83 | TheFly | Ascendis Pharma price target raised to $329 from $324 at Evercore ISI |
| May 11, 2026 9:18 am | — | Barclays | $345.00 | $238.66 | TheFly | Ascendis Pharma price target raised to $345 from $342 at Barclays |
| May 8, 2026 10:26 am | — | Wells Fargo | $326.00 | $246.14 | TheFly | Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo |
| March 5, 2026 9:18 pm | — | Jefferies | $262.00 | $237.35 | StreetInsider | Ascendis Pharma (ASND) PT Raised to $262 at BofA Securities |
| March 4, 2026 8:22 pm | Alex Thompson | Stifel Nicolaus | $332.00 | $241.38 | StreetInsider | Ascendis Pharma (ASND) PT Raised to $332 at Stifel |
| March 2, 2026 3:59 pm | Kalpit Patel | Wolfe Research | $260.00 | $231.46 | StreetInsider | Ascendis Pharma (ASND) PT Raised to $260 at Wolfe Research |
| March 2, 2026 3:38 pm | Li Watsek | Cantor Fitzgerald | $300.00 | $231.43 | StreetInsider | Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND) |
| March 2, 2026 3:03 pm | Josh Schimmer | Evercore ISI | $324.00 | $234.07 | StreetInsider | Ascendis Pharma (ASND) PT Raised to $324 at Evercore ISI |
| March 2, 2026 9:55 am | Paul Choi | Goldman Sachs | $255.00 | $233.50 | StreetInsider | Ascendis Pharma (ASND) PT Raised to $255 at Goldman Sachs |
Latest News for ASND
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
Let us begin with a midyear summary of index results that might surprise you in light of the triple-digit gains for so many growth stocks in the S&P 500.
COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including…
COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ASND.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.